Apparently the OPC assay study with Biogen in early 2017 wasn't successful since there was no follow up in vivo remylenation study, the path the company envisioned. Anyway the just-granted patent we applied for a couple years ago does cover Rett Syndrome treatment, which we will soon get top line results on.